ERBB2 and breast carcinoma: Silica nanoparticles loaded with anti-HER-2 scFv800E6 antibody showed a 4-fold increase in scFv binding efficacy in HER-2 antigen-positive MCF-7 breast cancer cell line, revealing the efficiency of the nanocarrier [168].